Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael Gnant
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial
Abstract Circulating tumor DNA (ctDNA) is a promising biomarker in early breast cancer for assessing treatment response, minimal residual disease (MRD), and recurrence risk. In the ABCSG-34 phase II trial, we previously reported that persistent ctDNA during neoadjuvant therapy (NAT) was associated with higher residual cancer burden and lower rates of pathological complete response. Here, we present long-term follow-up data evaluating the prognostic relevance of ctDNA dynamics.
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial | Nature Cancer
Abstract The role of anthracyclines in the treatment of early breast cancer (EBC) is increasingly being challenged, especially in de-escalation strategies. However, owing to their immunogenic effects, anthracyclines are promising combination partners with immunotherapies. In the randomized phase 2 trial ABCSG-52 (EudraCT no. 2019-002364-27), we investigated epirubicin plus immunotherapy in women with human epidermal growth factor receptor 2 (HER2)-positive EBC.
Standardized Definitions for Efficacy End Points for Adjuvant Trials-The Updated STEEP Criteria
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria The accurate and transparent reporting of clinical trial results is of the utmost importance to all stakeholders (clinicians, patients, regulatory agencies, the global scientific public) for several reasons.
Explained variation and degrees of necessity and of sufficiency for competing risks survival data
1 INTRODUCTION Explained variation measures the relative gain in predictive accuracy when prediction based on prognostic factors replaces unconditional prediction. The factors may be measured on different scales or may be of different types (dichotomous, qualitative, or continuous) but the result always is given on a 0–1 scale (Gleiss et al., 2016; Schemper & Henderson, 2000).
JMIR Formative Research - Assessing Knowledge, Competence, and Performance Following Web-Based Education on Early Breast Cancer Management: Health Care Professional Questionnaire Study and Anonymized Patient Records Analysis
Clinical Decision-Making in High-Risk Early Breast Cancer Effectiveness of Web-Based HCP Education in Breast Cancer Study Rationale, Objectives, and Aims Study Design Ethical Considerations Educational Activities Assessment of Educational Outcomes Levels 1 and 2 (Participation and Satisfaction) Levels 3 to 4 and Level 5 (Knowledge, Competence, and Performance) Self-Reported Confidence and Intention to Change Practice Identification of Outstanding Educational Gaps Fielding of the...
Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis
1 Introduction In France, breast cancer (BC) is the most prevalent cancer in women, with 58,083 new cases in 2020 (1). The most common subtype of BC, accounting for 70% of all female cases, is hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) BC (2, 3). Surgery followed by adjuvant systemic therapy is the mainstay of treatment for early BC.
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management - npj Breast Cancer
Abstract Breast cancer multigene signatures (BCMS) have changed how patients with early-stage breast cancer (eBC) are managed, as they provide prognostic information and can be used to select patients who may avoid adjuvant chemotherapy. Clinical guidelines make recommendations on the use of BCMS; however, little is known on the current use of BCMS in clinical practice.
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer
Abstract Background Adjuvant aromatase inhibitors increase osteoporosis and fractures in patients with hormone receptor–positive breast cancer. We have previously reported outcomes of the ABCSG-18 (study 18 from the Austrian Breast & Colorectal Cancer Study Group) trial showing that adjuvant anti–receptor activator of nuclear factor-κB ligand denosumab treatment counteracts these adverse effects and may improve outcomes. We report here the final long-term outcomes.
Palbociclib regimen fails to extend invasive DFS in early breast cancer
December 08, 2021 3 min read Save Source/Disclosures Published by: Source: Gnant M, et al. Abstract GS1-07. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio. Disclosures: Gnant reports a consultant role with LifeBrain, as well as personal fees and travel support from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Nanostring, Novartis, Pierre Fabre and TLC Biopharmaceuticals. He also reports an immediate family member is employed by Sandoz.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
Related Articles Abstract Background For postmenopausal women with hormone-receptor–positive breast cancer, the most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear. Methods Download a PDF of the Research Summary.
Prolonged adjuvant anastrozole confers no DFS benefit in postmenopausal breast cancer
July 28, 2021 3 min read Save Source/Disclosures Published by: Source: Gnant M, et al. N Engl J Med. 2021;doi:10.1056/NEJMoa2104162. Disclosures: AstraZeneca and Austrian Breast and Colorectal Cancer Study Group supported this study. Gnant reports consultant/advisory roles with Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Lifebrain, NanoString Technologies, Novartis, TLC and Tolmar Inc. He also reports his spouse is employed by Sandoz.
Correction: Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
Loading metrics Open Access Correction Elisabeth S. Gruber, Gerd Jomrich, Dietmar Tamandl, Michael Gnant, Martin Schindl, Klaus Sahora Elisabeth S. Gruber, Gerd Jomrich, Dietmar Tamandl, Michael Gnant, Martin Schindl, Klaus Sahora Published: December 29, 2020 https://doi.org/10.1371/journal.pone.0244896 There are errors in the author affiliations. The correct affiliations are as follows: Elisabeth S.
Warum hält man einen entlastenden Bericht unter Verschluss?
Cookies-Einstellungen Notwendige Cookies Unsere notwendigen Cookies sind zur Funktion der Website nötig und können daher nicht deaktiviert werden. Sonstige Cookies Wenn Sie allen Cookies zustimmen, ermöglicht Ihnen das die Verwendung unserer Community Features (Lesen und Verfassen von Kommentaren, Merkliste, sowie Seamless Reading) – und uns die Analyse des Userverhaltens und Verbesserung des User-Erlebnisses.
Breast cancer
1. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000). CAS Article Google Scholar 2. Cardoso, F. et al. European Breast Cancer Conference manifesto on breast centres/units. Eur. J. Cancer 72, 244–250 (2017). PubMed Article PubMed Central Google Scholar 3. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). PubMed Article PubMed Central Google Scholar 4.
New evidence and hope for young patients with breast cancer
Medical University of Vienna, Vienna, Austria Article Info Publication History Published online: July 30, 2019Accepted: June 24, 2019; Received: June 24, 2019; © 2019 Elsevier Ltd. All rights reserved.
Denosumab in early-stage breast cancer - Authors' reply
We appreciate the comments of Elena Rodriguez and colleagues on our report 1 Gnant M Pfeiler G Steger GG et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Summary Background In postmenopausal women with hormone receptor-positive, early-stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures. Results from the ABCSG-18 trial showed that use of denosumab as an adjuvant to aromatase inhibitor therapy significantly reduced clinical fractures. Disease-free survival outcomes from ABCSG-18 have not yet been reported.
Denosumab improves DFS, bone-related outcomes in breast cancer subtype
“Adjuvant aromatase inhibitors are [the] standard of care for postmenopausal women with HR-positive, early-stage breast cancer, but [the agents] cause osteoporosis and fractures,” the authors wrote. “ABCSG-18 showed previously that adjuvant denosumab significantly reduces clinical fractures.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack